Roche Seragon acquisition worth $1.725 billion agreed

Published: 06:08, July 2, 2014

A Roche Seragon acquisition has been agreed by the two companies. Seragon Pharmaceuticals, a San Diego based, privately-held biotech company that is developing small-molecule medications for the treatment of estrogen receptor dependent breast cancer, will be acquired by the Swiss giant, Roche Holding AG, for up to $1.725 billion.

Seragon Pharmaceuticals Inc. was spun out from Aragon Pharmaceuticals in 2013 when it was taken over by Johnson & Johnson. Seragon’s investors include the Column Group, Topspin, Aisling Capital, VenBio and OrbiMed.

According to Roche, Genentech, which it acquired in 2009 for $46.8 billion, and Seragon have entered a definitive acquisition agreement. The Swiss company wrote “With this acquisition, Genentech obtains rights to Seragon’s entire portfolio of investigational next-generation oral selective estrogen receptor degraders (SERDs), for the potential treatment of hormone receptor-positive breast cancer.”

Genentech Research and Early Development’s Executive Vice President, Richard Scheller, Ph.D., said:

“This year, breast cancer will claim the lives of nearly 40,000 women in the United States, and up to half of these women will have a disease that is driven by the estrogen receptor. We believe these investigational oral SERDs could one day redefine the standard of care for hormone receptor-positive breast cancer.”

Cash up front plus more tied to targets

The two companies have agreed that Genentech will:

  • pay $725 million in cash up front,
  • make additional payments up to $1 billion tied to certain predetermined milestones (targets).

Roche expects the transaction, which is subject to regulatory approval, to be concluded in Q3 2014.

Roche is a global leader in the treatment of breast cancer, with such medications as Herceptin (trastuzumab). About one-sixth of Roche’s revenues in 2013 came from Herceptin sales, which totaled SFr6 billion ($6.75 billion).

Perjeta and Kadcyla, drugs for treating patients whose cancerous cells contain higher levels of HER2 (a protein), were recently approved. So far this year, the two drugs have brought in SFr280 million ($315 million) in sales. Roche hopes they can replace the income loss it will incur when Herceptin’s patent expires.

Herceptin patent expiries

With Herceptin expiries looming, Roche needs to act rapidly to maintain its breast cancer market dominance.

Pricey but wise acquisition

$1.725 billion seems like an awful lot of money to pay for a company with only one experimental drug (ARN-810) that is still in Phase I.

However, by buying Seragon, Roche is now able to fill a giant gap for future breast cancer treatment. Seragon’s product portfolio targets more than half of patients who develop the disease.

Research and development (R&D) costs have risen considerably over the last ten years. In the search for the next blockbuster medication, drugmakers are today buying up smaller companies with promising molecules.

Roche has made some other acquisitions this year. Last month, the company agreed a $350 million deal to acquire Genia Technologies, a privately held DNA sequencing business. In May, agreement was reached to take over IQuum, a Massachusetts-based company that makes medical testing equipment.

F. Hoffmann-La Roche Ltd (the Roche Group) is headquartered in Basel, Switzerland. It employs more than 80,000 people worldwide.

Veronica Salvador Avatar

Other News

What virtual shopping tools can change before and after a purchase

Nov 19, 2026

Game-like loyalty features drew more engagement in an online grocery study

Nov 18, 2026

A delivery cue helped more shoppers move to the next checkout step

Nov 18, 2026

Small changes in a store can bring promotions back to repeat customers’ attention

Nov 18, 2026

Some sellers accept less when a buyer shares an item’s heritage

Nov 18, 2026

Changing a marketplace trust badge can change what sellers prioritize

Nov 18, 2026

Referred customers may bring in more customers of their own

Nov 18, 2026

An extra option can make an attractive menu less appealing, experiments find

Nov 17, 2026

Adding similar choices can change which products look like the middle option

Nov 17, 2026

World Bank plans e-commerce pilot for small firms in three West African countries

Nov 17, 2026

Contextual ads were the most common targeting method among EU online advertisers

Nov 17, 2026

People treat the same money differently across spending categories, study finds

Nov 17, 2026

Small-business loan applications can stall before they are formally submitted

Nov 17, 2026

Describing the parts of an experience can change how much people enjoy it

Nov 16, 2026

A prize can feel different when customers know they might have received less

Nov 16, 2026

Frequent rating requests can change how customers experience a service

Nov 16, 2026

How a business handles customer data can shape its relationship with buyers

Nov 16, 2026

Trying a customized product can shape what shoppers choose later

Nov 16, 2026

Why the way unit prices are shown can change how shoppers judge a deal

Nov 16, 2026

Why the weather can affect ratings of cold-weather gear

Nov 15, 2026